Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945569 | 1.00 | CES2 (0.50) | CES2CES1ITGB3ITGA2BMME | |
| SCHEMBL7809416 | 0.83 | GABBR2 (0.47) | CES2CES1ITGB3ITGA2BMME | |
| SCHEMBL6938034 | 0.80 | FFAR1 (0.50) | CES2CES1ITGB3ITGA2BMME | |
| SCHEMBL17841359 | 0.80 | KMT2A (0.46) | CES2CES1ITGB3ITGA2BMME | |
| SCHEMBL7951522 | 0.80 | KMT2A (0.46) | CES2CES1ITGB3ITGA2BMME | |
| SCHEMBL17857504 | 0.80 | KMT2A (0.46) | CES2CES1ITGB3ITGA2BMME | |
| SCHEMBL20967754 | 0.80 | CES2 (0.45) | CES2CES1MMEADRB1ADRA2A | |
| SCHEMBL30955364 | 0.80 | CES2 (0.45) | CES2CES1MMEADRB1ADRA2A | |
| SCHEMBL8770875 | 0.80 | CES2 (0.45) | CES2CES1MMEADRB1ADRA2A | |
| SCHEMBL20576275 | 0.79 | GRM8 (0.52) | FFAR1LMNATSHRRECQLHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278809-B | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3704097-B1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3704097-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-0451668-B1 | Process for the production of optically active alkyl 3-aryl-3-hydroxypropionates | CHISSO CORP (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5202457-A | Enzyme catalyzed transesterification, resolution of optical active alkyl 3-aryl-3-hydroxypropionate | CHISSO CORPORATION (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0451668-A2 | Optically active alkyl 3-aryl-3-hydroxypropionates and a method for producing thereof | CHISSO CORPORATION (JP) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | RB1, CCNE2, RPS3A | CES2 3471/4885CES1 2941/4885ITGB3 4060/4885 |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | RB1, CCNE2, RPS3A | CES2 3471/4885CES1 2941/4885ITGB3 4060/4885 |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | RB1, CCNE2, RPS3A | CES2 3471/4885CES1 2941/4885ITGB3 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.